Expression Systems

Monday, February 25, 2013, 10:15am-12:20pm PST

The focus of this session will be the use of expression systems to significantly accelerate development and eventual commercialization of protein therapeutics.  Talks might include discussion of current use (or potential use) of novel expression systems for this purpose, or the use of conventional expression systems in a different manner to achieve acceleration.  

Session Co-Chairs: 

  • Tim Charlebois, Pfizer
  • Thomas Ryll, Biogen Idec

 

Confirmed Speakers

  • Arvia Morris, Amgen: Efficient upstream process development programs generated using early molecule assessment and culture of continuous improvement
  • Amy Shen, Genentech: Past and Present Strategies, Challenges, and Benefits of Stable Cell Line Development at Genentech
  • Martin Allen, Pfizer: Streamlining the Discovery to Development Transition
  • Rashmi Kshirsagar: Integration of Cell Culture Process Platform and Cell Line Expression Systems to accelerate Biopharmaceutical Development

Arvia Morris

After finishing her post doc work in the laboratory of Lawrence Chasin, Arvia has contributed to upstream process programs for Immunex and Amgen.  Her areas of interest include vector development, media development, process implementation and raw material evaluation.